• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较患有和未患有多发性硬化症的患者发生严重感染的风险:一项德国索赔数据分析。

Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.

作者信息

Knapp Rachel, Hardtstock Fränce, Wilke Thomas, Maywald Ulf, Chognot Cathy, Craveiro Licinio, Rouzic Erwan Muros-Le

机构信息

Cytel Inc., Potsdamer Straße 58, 10785, Berlin, Germany.

Cytel Inc., Potsdamer Straße 58, 10785, Berlin, Germany.

出版信息

Mult Scler Relat Disord. 2023 Apr;72:104583. doi: 10.1016/j.msard.2023.104583. Epub 2023 Feb 21.

DOI:10.1016/j.msard.2023.104583
PMID:36905817
Abstract

BACKGROUND

Research suggests that serious infections (SIs), comorbidities, and advanced disability represent key drivers of early death in people with Multiple Sclerosis (pwMS). Nevertheless, further research is warranted to better characterize and quantify the risk of SI among pwMS compared to the general population.

METHODS

Our study consisted of a retrospective analysis of claims data provided by a German statutory health insurance fund, AOK PLUS, covering 3.4 million individuals in Saxony and Thuringia from 01/01/2015-31/12/2019. A propensity score (PS) matching method was used to compare the incidence of SIs among people with and without MS. PwMS were required to have ≥1 inpatient or ≥2 confirmed outpatient diagnoses of MS (ICD-10 G35) from a neurologist from 01/01/2016-31/12/2018, while people from the general population could not have any inpatient/outpatient codes for MS during the entire study period. The index date was defined as the first observed MS diagnosis or, in the case of the non-MS cohort, a randomly assigned date within the inclusion period. For both cohorts a PS was assigned, corresponding with their probabilistic likelihood of having MS based on observable factors including patient characteristics, comorbidities, medication use and other variables. People with and without MS were matched using a 1:1 nearest neighbor strategy. An exhaustive list of ICD-10 codes was created in association with 11 main SI categories. SIs were those recorded as the main diagnosis during an inpatient stay. ICD-10 codes from the 11 main categories were sorted into smaller classification units, used to distinguish between infections. A 60-day threshold for measuring new cases was defined to account for the potential risk of re-infection. Patients were observed until the end of the study period (31/12/2019) or death. Cumulative incidence, incidence rates (IRs) and IR ratios (IRRs) were reported during follow-up and at 1-, 2- and 3-years post-index.

RESULTS

A total of 4250 and 2,098,626 patients were included in the unmatched cohorts of people with and without MS. Ultimately, one match was identified for all 4,250 pwMS, corresponding with a final population of 8,500 patients. On average, patients were 52.0/52.2 years in the matched MS/non-MS cohorts; the gender breakdown was 72% female. Overall, IRs of SIs per 100 patient years (PY) were higher in pwMS than in those without MS (1 year: 7.6 vs. 4.3; 2 years: 7.1 vs. 3.8; 3 years: 6.9 vs. 3.9). During follow-up, the most common infection types in pwMS were of a bacterial/parasitic origin (2.3 per 100 PY), followed by respiratory (2.0) and genitourinary (1.9) infections. Respiratory infections were most common in patients without MS (1.5 per 100 PY). Differences in the IRs of SIs were statistically significant (p<0.01) at each measurement window, with IRRs ranging from 1.7-1.9. PwMS had a higher risk of hospitalized genitourinary infections (IRR: 3.3-3.8) and bacterial/parasitic infections (2.0-2.3).

CONCLUSIONS

The incidence of SIs is much higher in pwMS, than comparators from the general population in Germany. Differences in hospitalized infection rates were largely driven by higher levels of bacterial/parasitic and genitourinary infections in the MS population.

摘要

背景

研究表明,严重感染(SIs)、合并症和严重残疾是多发性硬化症患者(pwMS)早期死亡的关键驱动因素。然而,仍有必要进行进一步研究,以更好地描述和量化pwMS与普通人群相比发生SI的风险。

方法

我们的研究包括对德国法定健康保险基金AOK PLUS提供的索赔数据进行回顾性分析,该数据涵盖了2015年1月1日至2019年12月31日期间萨克森州和图林根州的340万人。采用倾向评分(PS)匹配方法比较有和没有MS的人群中SI的发生率。要求pwMS在2016年1月1日至2018年12月31日期间有≥1次住院或≥2次经神经科医生确诊的门诊MS诊断(ICD-10 G35),而普通人群在整个研究期间不能有任何MS的住院/门诊编码。索引日期定义为首次观察到的MS诊断日期,或者在非MS队列中,为纳入期内随机分配的日期。为两个队列都分配了一个PS,这与他们基于可观察因素(包括患者特征、合并症、药物使用和其他变量)患MS的概率可能性相对应。有和没有MS的人使用1:1最近邻策略进行匹配。创建了一份与11个主要SI类别相关的ICD-10编码详尽列表。SI是指住院期间记录为主要诊断的那些。来自11个主要类别的ICD-10编码被分类为更小的分类单元,用于区分感染。定义了一个60天的新病例测量阈值,以考虑再感染的潜在风险。观察患者直至研究期结束(2019年12月31日)或死亡。在随访期间以及索引后1年、2年和3年报告累积发病率、发病率(IRs)和IR比值(IRRs)。

结果

共有4250名和2,098,626名患者分别纳入了未匹配的有和没有MS的队列。最终,为所有4250名pwMS都找到了一个匹配对象,对应最终的8500名患者群体。在匹配的MS/非MS队列中,患者平均年龄为52.0/52.2岁;性别分布为72%为女性。总体而言,pwMS每100人年(PY)的SI发病率高于没有MS的人(1年:7.6对4.3;2年:7.1对3.8;3年:6.9对3.9)。在随访期间,pwMS中最常见的感染类型是细菌/寄生虫源性感染(每100 PY为2.3次),其次是呼吸道感染(2.0次)和泌尿生殖系统感染(1.9次)。呼吸道感染在没有MS的患者中最为常见(每100 PY为1.5次)。在每个测量窗口,SI发病率的差异具有统计学意义(p<0.01),IRR范围为1.7 - 1.9。pwMS发生住院泌尿生殖系统感染(IRR:3.3 - 3.8)和细菌/寄生虫感染(2.0 - 2.3)的风险更高。

结论

pwMS中SI的发生率远高于德国普通人群中的对照者。住院感染率的差异在很大程度上是由MS人群中较高水平的细菌/寄生虫感染和泌尿生殖系统感染所驱动的。

相似文献

1
Comparing the risk of serious infections in patients with and without MS: A German claims data analysis.比较患有和未患有多发性硬化症的患者发生严重感染的风险:一项德国索赔数据分析。
Mult Scler Relat Disord. 2023 Apr;72:104583. doi: 10.1016/j.msard.2023.104583. Epub 2023 Feb 21.
2
Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.复发型和进展型多发性硬化症患者的严重感染:一项德国索赔数据研究。
Mult Scler Relat Disord. 2022 Dec;68:104245. doi: 10.1016/j.msard.2022.104245. Epub 2022 Oct 17.
3
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.用奥瑞珠单抗治疗的多发性硬化症患者感染及相关危险因素的长期分析:13项介入性临床试验的汇总分析
Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736. eCollection 2024.
4
Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.电子健康记录数据用于评估 COVID-19 住院风险:应用于多发性硬化症的方法学考虑。
Mult Scler Relat Disord. 2023 Mar;71:104512. doi: 10.1016/j.msard.2023.104512. Epub 2023 Jan 11.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.与奥瑞珠单抗相比,富马酸二甲酯的感染率较低,与感染相关的医疗保健费用也较低。
Mult Scler Relat Disord. 2022 Jul;63:103921. doi: 10.1016/j.msard.2022.103921. Epub 2022 Jun 2.
7
Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany.儿童、青少年和成年人的新冠后并发症:一项匹配队列研究,纳入了德国超过 157000 例新冠患者。
PLoS Med. 2022 Nov 10;19(11):e1004122. doi: 10.1371/journal.pmed.1004122. eCollection 2022 Nov.
8
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险:一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
9
Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.复发缓解型多发性硬化症患者的流行病学、特征和治疗以及高疾病活动度的发生率:基于德国索赔数据的真实世界证据。
PLoS One. 2020 May 1;15(5):e0231846. doi: 10.1371/journal.pone.0231846. eCollection 2020.
10
Infections in patients diagnosed with multiple sclerosis: A multi-database study.多发性硬化症患者的感染:一项多数据库研究。
Mult Scler Relat Disord. 2020 Jun;41:101982. doi: 10.1016/j.msard.2020.101982. Epub 2020 Feb 4.

引用本文的文献

1
MS treatment de-escalation: review and commentary.多发性硬化症治疗的逐步降级:综述与评论
J Neurol. 2024 Oct;271(10):6426-6438. doi: 10.1007/s00415-024-12584-x. Epub 2024 Aug 2.